People: use cases, players, stakeholders.
Common regulatory triggers that may require a BE study · the five player categories that run the field · ten stakeholder roles. Who decides, who pays, who is liable in BE 2026.
Use cases: what BE is actually for.
Common regulatory triggers that may require a BE studyIn submission use, BE is regulated evidence work, not only research activity. It is usually triggered by specific submission pathways. The trigger determines the design (single vs multiple dose, fasted vs fed, full vs partial replicate), the reference product (RLD vs Member State innovator vs Brazilian RP), the timeline, and the inspection regime that will eventually look at the data.
ANDA filing.
The original use case. US generic sponsor files Abbreviated New Drug Application against the Reference Listed Drug. Single fasted study minimum; fed study added per FDA product-specific guidance. The trigger that built the entire BE CRO industry.
EU generic registration.
Centralised, decentralised, mutual-recognition or national procedure. Reference product sourced from a Member State. EMA CPMP/EWP/QWP/1401/98 the canonical guidance. Member State regulator inspects the BE site directly.
Biosimilar PK bridging.
Comparative PK against reference biologic. Same TOST principle but executed on biologic plasma assays (LBA / hybrid LC-MS). Immunogenicity package runs in parallel.
Brazil generic registration.
ANVISA generic or similar registration. Reference product from Brazilian list. Brazilian healthy-volunteer registry constraints. CRO inspection regime distinctive.
Post-approval change.
Manufacturing site change, formulation modification, scale-up. SUPAC-IR / EMA variation Type II. BE bridging study against pre-change reference. Common ongoing pharma trigger across product lifecycle.
Biowaiver filing.
BCS Class I or III biowaiver. In vitro dissolution f2 instead of in vivo BE. Excipient effect assessment (post-M9). Most cost-effective path when BCS scope permits.
WHO prequalification.
Anti-TB, anti-HIV, anti-malarial multisource generics. Reference product from WHO Comparator Product List. Annex 7 acceptance bound. LMIC public-health pathway.
India generic registration.
India-marketed innovator as reference. Schedule Y / 2018 BE Guideline. CDSCO BA-BE Centre approval. Volume of work concentrated in a narrow set of accredited Indian CROs.
Big players: who runs the field.
CROs · generics · regulators · tech · standardsThe BE ecosystem has five player categories. Generic-drug pharma sets the strategy and pays; CRO BE specialists execute most studies; regulators define the surface; tech vendors own the LIMS/EDC infrastructure; standards bodies set the harmonised guidance. Each category has a distinct centre of gravity.
Stakeholders: interests & leverage.
Who decides · who pays · who is affectedEach stakeholder in a BE programme has a distinct interest and a distinct lever. Reading the operating context means knowing who responds when the study is challenged — whether by a regulatory question, inspection observation, site finding, or volunteer adverse event. Ten roles cover the field.
Official source register.
Regulator / ICH anchorsICH M13A bioequivalence guideline.
Official FDA-hosted page for ICH M13A on bioequivalence for immediate-release solid oral dosage forms. Use as the first harmonised anchor for conventional oral IR BE framing.
BCS-based biowaiver guidance.
Official ICH M9 Step 4 guideline. Use for BCS classification, solubility/permeability thinking, and eligible biowaiver conditions.
Bioanalytical method validation and study sample analysis.
Official ICH M10 Step 4 guideline. Use for the bioanalytical evidence layer that supports BA/BE concentration data.
Product-specific guidances for generic development.
FDA product-specific guidance collection. Use before protocol lock because product-level recommendations can change design, fed/fasted, analyte, and BE expectations.
US bioavailability and bioequivalence regulation.
Electronic Code of Federal Regulations anchor for US BA/BE definitions and requirements. Use for statutory/regulatory context, not as a complete study-design manual.
Guideline on the investigation of bioequivalence.
EMA scientific guideline landing page for BE investigation. Use for EU framing, while checking product-specific or updated procedural context where relevant.
Multisource generic products and interchangeability.
WHO IRIS record for multisource pharmaceutical product guidance. Use as a WHO anchor for generic interchangeability and BE expectations in broader access settings.